Royalty Pharma plc (RPRX) Q2 FY26 Earnings Call

Management raised 2026 guidance again, with royalty-receipts growth now expected at 7%-10%. [23]

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-05
Length52 minutes
EPS$1.32
EPS consensus$1.27
Revenue$630.6M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25

All RPRX earnings ยท Back to RPRX overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.